Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy

• Published in: Light, science & applications Vol. 9; no. 1; p. 161
• Main Authors: Xie, Zhongjian, Peng, Minhua, Lu, Ruitao, Meng, Xiangying, Liang, Weiyuan, Li, Zhongjun, Qiu, Meng, Zhang, Bin, Nie, Guohui, Xie, Ni, Zhang, Han, Prasad, Paras N.
• Format: Journal Article
• Language: English
• Published: London Springer Nature B.V 15.09.2020; Nature Publishing Group UK
• Subjects: Antitumor activity; Cancer; Cancer immunotherapy; Cancer therapies; Cell proliferation; Clinical trials; Immune checkpoint; Immune response; Immune system; Immunogenicity; Immunotherapy; Metastases; Phagocytes; Phosphorus; Solid tumors; Tumor microenvironment; Tumors
• ISSN: 2047-7538; 2095-5545; 2047-7538
• DOI: 10.1038/s41377-020-00388-3

Abstract Here, we describe a combination strategy of black phosphorus (BP)-based photothermal therapy together with anti-CD47 antibody (aCD47)-based immunotherapy to synergistically enhance cancer treatment. Tumour resistance to immune checkpoint blockades in most cancers due to immune escape from host surveillance, along with the initiation of metastasis through immunosuppressive cells in the tumour microenvironment, remains a significant challenge for cancer immunotherapy. aCD47, an agent for CD47/SIRPα axis blockade, induces modest phagocytic activity and a low response rate for monotherapy, resulting in failures in clinical trials. We showed that BP-mediated ablation of tumours through photothermal effects could serve as an effective strategy for specific immunological stimulation, improving the inherently poor immunogenicity of tumours, which is particularly useful for enhancing cancer immunotherapy. BP in combination with aCD47 blockade activates both innate and adaptive immunities and promotes local and systemic anticancer immune responses, thus offering a synergistically enhanced effect in suppression of tumour progression and in inducing abscopal effects for inhibition of metastatic cancers. Our combination strategy provides a promising platform in which photothermal agents could help to enhance the therapeutic efficacy of immunotherapy.